354 related articles for article (PubMed ID: 15705738)
1. WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity.
Dunlop J; Sabb AL; Mazandarani H; Zhang J; Kalgaonker S; Shukhina E; Sukoff S; Vogel RL; Stack G; Schechter L; Harrison BL; Rosenzweig-Lipson S
J Pharmacol Exp Ther; 2005 May; 313(2):862-9. PubMed ID: 15705738
[TBL] [Abstract][Full Text] [Related]
2. WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity.
Marquis KL; Sabb AL; Logue SF; Brennan JA; Piesla MJ; Comery TA; Grauer SM; Ashby CR; Nguyen HQ; Dawson LA; Barrett JE; Stack G; Meltzer HY; Harrison BL; Rosenzweig-Lipson S
J Pharmacol Exp Ther; 2007 Jan; 320(1):486-96. PubMed ID: 17038512
[TBL] [Abstract][Full Text] [Related]
3. Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist.
Dunlop J; Watts SW; Barrett JE; Coupet J; Harrison B; Mazandarani H; Nawoschik S; Pangalos MN; Ramamoorthy S; Schechter L; Smith D; Stack G; Zhang J; Zhang G; Rosenzweig-Lipson S
J Pharmacol Exp Ther; 2011 Jun; 337(3):673-80. PubMed ID: 21402690
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological profile of the 5-HT(2C) receptor agonist WAY-163909; therapeutic potential in multiple indications.
Dunlop J; Marquis KL; Lim HK; Leung L; Kao J; Cheesman C; Rosenzweig-Lipson S
CNS Drug Rev; 2006; 12(3-4):167-77. PubMed ID: 17227285
[TBL] [Abstract][Full Text] [Related]
5. Anxiolytic activity of a novel potent serotonin 5-HT2C receptor antagonist FR260010: a comparison with diazepam and buspirone.
Harada K; Aota M; Inoue T; Matsuda R; Mihara T; Yamaji T; Ishibashi K; Matsuoka N
Eur J Pharmacol; 2006 Dec; 553(1-3):171-84. PubMed ID: 17074317
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo pharmacological characterization of PF-01354082, a novel partial agonist selective for the 5-HT(4) receptor.
Mikami T; Komada T; Sugimoto H; Suzuki K; Ohmi T; Kimura N; Naganeo R; Nakata E; Nakatani K; Toga T; Eda H; Sakakibara M
Eur J Pharmacol; 2009 May; 609(1-3):5-12. PubMed ID: 19285067
[TBL] [Abstract][Full Text] [Related]
7. S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization.
Millan MJ; Mannoury la Cour C; Chanrion B; Dupuis DS; Di Cara B; Audinot V; Cussac D; Newman-Tancredi A; Kamal M; Boutin JA; Jockers R; Marin P; Bockaert J; Muller O; Dekeyne A; Lavielle G
J Pharmacol Exp Ther; 2012 Mar; 340(3):750-64. PubMed ID: 22178752
[TBL] [Abstract][Full Text] [Related]
8. Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161503.
Rosenzweig-Lipson S; Zhang J; Mazandarani H; Harrison BL; Sabb A; Sabalski J; Stack G; Welmaker G; Barrett JE; Dunlop J
Brain Res; 2006 Feb; 1073-1074():240-51. PubMed ID: 16430874
[TBL] [Abstract][Full Text] [Related]
9. (+)-WAY 100135, a partial agonist, at native and recombinant 5-HT1B/1D receptors.
Davidson C; Ho M; Price GW; Jones BJ; Stamford JA
Br J Pharmacol; 1997 Jun; 121(4):737-42. PubMed ID: 9208142
[TBL] [Abstract][Full Text] [Related]
10. Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents.
Ahmad S; Ngu K; Miller KJ; Wu G; Hung CP; Malmstrom S; Zhang G; O'Tanyi E; Keim WJ; Cullen MJ; Rohrbach KW; Thomas M; Ung T; Qu Q; Gan J; Narayanan R; Pelleymounter MA; Robl JA
Bioorg Med Chem Lett; 2010 Feb; 20(3):1128-33. PubMed ID: 20022752
[TBL] [Abstract][Full Text] [Related]
11. WAY-100635 antagonist-induced plasticity of 5-HT receptors: regulatory differences between a stable cell line and an in vivo native system.
Khawaja XZ; Smith DL; Nawoschik SP; Zhang J; Dunlop J; Dilks DW; Olsen M; Schechter LE
J Neurochem; 2006 Jul; 98(1):134-45. PubMed ID: 16805803
[TBL] [Abstract][Full Text] [Related]
12. Cycloalkyl[b][1,4]benzodiazepinoindoles are agonists at the human 5-HT2C receptor.
Sabb AL; Vogel RL; Welmaker GS; Sabalski JE; Coupet J; Dunlop J; Rosenzweig-Lipson S; Harrison B
Bioorg Med Chem Lett; 2004 May; 14(10):2603-7. PubMed ID: 15109661
[TBL] [Abstract][Full Text] [Related]
13. Effects of mu-CPP and mesulergine on dietary choices in deprived rats: possible mechanisms of their action.
Antonatos S; Galanopoulou P
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jan; 30(1):112-9. PubMed ID: 16242827
[TBL] [Abstract][Full Text] [Related]
14. Ejaculatory response induced by a 5-HT2 receptor agonist m-CPP in rats: differential roles of 5-HT2 receptor subtypes.
Yonezawa A; Yoshizumi M; Ebiko M; Ise SN; Watanabe C; Mizoguchi H; Kimura Y; Sakurada S
Pharmacol Biochem Behav; 2008 Feb; 88(4):367-73. PubMed ID: 17936345
[TBL] [Abstract][Full Text] [Related]
15. Effects of the serotonin 5-HT2A and 5-HT2C receptor ligands on the discriminative stimulus effects of nicotine in rats.
Zaniewska M; McCreary AC; Przegaliński E; Filip M
Eur J Pharmacol; 2007 Oct; 571(2-3):156-65. PubMed ID: 17617403
[TBL] [Abstract][Full Text] [Related]
16. The pharmacological profile of (R)-3,4-dihydro-N-isopropyl-3-(N-isopropyl-N-propylamino)-2H-1-benzopyran-5-carboxamide, a selective 5-hydroxytryptamine(1A) receptor agonist.
Rënyi L; Evenden JL; Fowler CJ; Jerning E; Kelder D; Lake-Bakaar D; Larsson LG; Mohell N; Sällemark M; Ross SB
J Pharmacol Exp Ther; 2001 Dec; 299(3):883-93. PubMed ID: 11714872
[TBL] [Abstract][Full Text] [Related]
17. Roles of 5-hydroxytryptamine (5-HT) receptor subtypes in the inhibitory effects of 5-HT on C-fiber responses of spinal wide dynamic range neurons in rats.
Liu FY; Xing GG; Qu XX; Xu IS; Han JS; Wan Y
J Pharmacol Exp Ther; 2007 Jun; 321(3):1046-53. PubMed ID: 17329553
[TBL] [Abstract][Full Text] [Related]
18. Characterizing the effects of 5-HT(2C) receptor ligands on motor activity and feeding behaviour in 5-HT(2C) receptor knockout mice.
Fletcher PJ; Tampakeras M; Sinyard J; Slassi A; Isaac M; Higgins GA
Neuropharmacology; 2009 Sep; 57(3):259-67. PubMed ID: 19501602
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y(1) receptor antagonist.
Antal-Zimanyi I; Bruce MA; Leboulluec KL; Iben LG; Mattson GK; McGovern RT; Hogan JB; Leahy CL; Flowers SC; Stanley JA; Ortiz AA; Poindexter GS
Eur J Pharmacol; 2008 Aug; 590(1-3):224-32. PubMed ID: 18573246
[TBL] [Abstract][Full Text] [Related]
20. Affinity of cyamemazine metabolites for serotonin, histamine and dopamine receptor subtypes.
Benyamina A; Arbus C; Nuss P; Garay RP; Neliat G; Hameg A
Eur J Pharmacol; 2008 Jan; 578(2-3):142-7. PubMed ID: 17936750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
